product Description
Daridorexant hydrochloride, sold under the brand name Quviviq, is a novel dual orexin receptor antagonist (DORA) approved for the treatment of insomnia in adults. It represents a new class of sleep medications that work by specifically targeting the orexin system in the brain, rather than causing general central nervous system (CNS) sedation like traditional hypnotics.
Basic Information & Chemical Properties
|
Item |
Details |
|
Drug Class |
Small molecule dual orexin receptor antagonist (DORA) |
|
Chemical Name |
(S)-(2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride |
|
Molecular Formula |
C₂₃H₂₄Cl₂N₆O₂ |
|
Molecular Weight |
487.38 g/mol |
|
CAS Number |
1792993-84-0 |
|
Physical Appearance |
White to pale yellow powder, slightly soluble in water |
|
Brand Name |
Quviviq (Idorsia Pharmaceuticals) |
|
Development Code |
ACT-541468 |
|
Other impurities |
≤0.1% |
|
Related Substances - Total Impurities |
≤1.0% |
|
Main peak purity |
≥99.0% |
|
Chiral purity |
≥99.0% |
|
Loss on drying |
≤0.5% |
|
Residue on ignition |
≤0.1% |
|
Heavy metals |
≤10ppm |
|
Storage |
Sealed and stored at room temperature. |
Key Advantages Over Traditional Hypnotics
- Targeted mechanism: Specifically addresses hyperarousal without general CNS depression
- Sleep stage preservation: Maintains natural sleep architecture
- Minimal next-day effects: Short half-life (~8 hours) reduces morning grogginess
- Lower abuse potential: Schedule IV classification vs. Schedule II for some benzodiazepines
- Sustained efficacy: Demonstrated effectiveness in clinical trials up to 12 months without tolerance development.
description2